Cardiac Tamponade During Tocilizumab Therapy in a Patient with Rheumatoid Arthritis and Anti-DNA Antibody Positivity

Intern Med. 2021 Oct 15;60(20):3245-3249. doi: 10.2169/internalmedicine.7166-21. Epub 2021 Mar 29.

Abstract

Drug-induced lupus (DIL) is a drug-mediated immune reaction with the same symptoms as that of lupus erythematosus. We herein report the first case of tocilizumab-induced lupus syndrome presenting with cardiac tamponade. A 65-year-old man presented with cough, exertional dyspnea, and chest pain after 2 months of tocilizumab therapy for rheumatoid arthritis. Echocardiography revealed marked pericardial effusion. Antinuclear antibodies and anti-double-stranded deoxyribonucleic acid antibodies were positive. The diagnosis of cardiac tamponade due to tocilizumab-induced lupus syndrome was made. He had no recurrence of pericardial effusion after tocilizumab discontinuation. Clinicians should be alert for lupus syndrome in patients receiving tocilizumab.

Keywords: adverse effect; case report; drug-induced lupus; interleukin-6; pericardial effusion; rheumatoid arthritis; tocilizumab.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Arthritis, Rheumatoid* / drug therapy
  • Cardiac Tamponade* / chemically induced
  • Cardiac Tamponade* / diagnosis
  • Humans
  • Lupus Erythematosus, Systemic* / chemically induced
  • Lupus Erythematosus, Systemic* / diagnosis
  • Lupus Erythematosus, Systemic* / drug therapy
  • Male

Substances

  • Antibodies, Monoclonal, Humanized
  • tocilizumab